منابع مشابه
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Blocking estrogen receptors with antiestrogens and blocking estrogen synthesis with aromatase inhibitors are two strategies currently being used for reducing the effect of estrogen in postmenopausal estrogen receptor-positive breast cancer patients. To optimize these treatment strategies, we have investigated whether tumor progression can be delayed by combining the pure antiestrogen fulvestran...
متن کاملAppraising adjuvant aromatase inhibitor therapy.
Tamoxifen, once the gold standard adjuvant endocrine therapy for early breast cancer, is being challenged by third-generation aromatase inhibitors (AIs) that have demonstrated improved disease-free survival in a variety of adjuvant settings for early breast cancer. Tamoxifen and AIs have different safety profiles, which should allow physicians to begin to individualize treatment based on a pati...
متن کاملAromatase inhibitor-associated bone loss.
273 A 49-year-old postmenopausal Caucasian woman named M.A. was diagnosed with estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, HER2-negative breast cancer. Anthracycline and taxane-based adjuvant chemotherapy and radiation therapy were followed by adjuvant therapy with an aromatase inhibitor (AI). Before M.A. started adjuvant AI therapy, she was evaluated for any additiona...
متن کاملAromatase over expression transgenic murine models for aromatase inhibitor studies.
In recent years the emerging importance of estrogen signaling in males in addition to its major role in the female reproductive system became highlighted. Aromatase is the key enzyme for synthesis of estrogens from androgens and is responsible for controlling the androgen/estrogen ratio. Inhibition of aromatase gene expression can be achieved in different ways and is important for the treatment...
متن کاملEnhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer.
BACKGROUND We have found that the platelet-derived growth factor receptor (PDGFR)/Abl signaling pathway is up-regulated as a determinant of the acquisition of resistance to estrogen deprivation in vitro. We aimed to determine its clinical relevance in aromatase inhibitor (AI)-resistant breast cancer. PATIENTS AND METHODS We identified a cohort of 45 patients with estrogen receptor-positive br...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacogenetics and Genomics
سال: 2009
ISSN: 1744-6872
DOI: 10.1097/fpc.0b013e32832e0ec1